<DOC>
	<DOCNO>NCT00001116</DOCNO>
	<brief_summary>The purpose study determine TNFR : Fc ( molecule attache TNF ) low amount IL-6 HIV-positive patient . This study also examine effect TNFR : Fc TNF-alpha . IL-6 TNF-alpha 2 substance produce immune system may increase rate HIV replication . IL-6 TNF-alpha produce naturally body . High level TNF-alpha lead increase IL-6 production increase HIV replication , therefore help virus infect body . HIV-positive patient receive IL-2 ( interleukin-2 , protein help immune system fight infection ) tend high level IL-6 TNF-alpha patient receive IL-2 . These increase level may contribute flu-like symptom relate IL-2 administration . TNFR : Fc neutralize TNF-alpha decrease action TNF-alpha , turn , decrease amount IL-6 body . TNFR : Fc may , therefore , role treatment HIV disease relieve symptom relate IL-2 administration .</brief_summary>
	<brief_title>A Study Evaluate Ability TNFR : Fc Decrease Amount IL-6 ( Interleukin-6 ) TNF-alpha ( Tumor Necrosis Factor ) HIV-Infected Patients</brief_title>
	<detailed_description>Both Interleukin-6 ( IL-6 ) Tumor necrosis factor-alpha ( TNF-alpha ) substance naturally produce body 's immune system . Evidence suggest TNF-alpha production may excessive inappropriate HIV-infected patient . Elevated TNF-alpha level result increase IL-6 production possibly increase HIV replication . TNFR : Fc modification natural substance bind TNF-alpha neutralizes activity . It postulate TNFR : Fc may result decreased activity TNF-alpha low IL-6 level . HIV-infected patient receive Interleukin-2 ( IL-2 ) show high TNF-alpha IL-6 level receive IL-2 . It think high level TNF-alpha IL-6 may contribute flu-like symptom experience patient receive IL-2 . By decrease amount IL-6 body decrease action TNF-alpha body , TNFR : Fc may role treatment HIV disease alleviate symptom relate IL-2 administration . Six patient 3 treatment arm ACTG 328 ( HAART alone , HAART plus intravenous ( IV ) rhIL-2 , HAART plus subcutaneous ( SC ) rhIL-2 ) randomize Step II ACTG 328 may participate prospective , nested substudy . Patients randomize Interleukin-2 ( IL-2 ) arm ACTG 328 pretreated TNFR : Fc ( administer infusion 30 minute ) week 16 ACTG 928 ( Course 3 , Week 28 ACTG 328 ) , prior initiation IL-2 . Those randomized highly active antiretroviral therapy ( HAART ) arm ACTG 328 receive treatment TNFR : Fc Week 16 ACTG 928 ( Week 28 ACTG 328 ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are HIVpositive . Are enrol ACTG 328 . Agree practice abstinence use barrier method birth control study . Are least 18 year old . Exclusion Criteria You eligible study : Have active opportunistic ( HIVassociated ) infection . Have medical condition psychological issue would interfere study requirement . Are pregnant breastfeeding . Are receive experimental drug IL2 . Are receive certain medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Tumor Necrosis Factor</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>Immunity , Cellular</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Interleukin-6</keyword>
	<keyword>Receptors , Tumor Necrosis Factor</keyword>
</DOC>